Posted in Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma April 13, 2026 Pharmaceutical Business Review The decision affects Replimune’s lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response. RegulatoryOncologyRead full story